NeoGenomics Integrates with Epic Aura to Expand Oncology Testing Reach
Event summary
- NeoGenomics’ oncology testing portfolio is now accessible through Epic Aura, a widely used electronic health record (EHR) system.
- The integration allows physicians to order NeoGenomics tests and view results directly within the Epic workflow.
- NeoGenomics anticipates a potential 20-30% increase in test adoption per site as a result of the integration.
- The integration supports NeoGenomics’ digital health strategy and enables delivery of next-generation diagnostics like liquid biopsy and MRD.
The big picture
NeoGenomics’ integration with Epic Aura represents a strategic shift towards greater accessibility and scalability within the fragmented oncology diagnostics market. By embedding its testing services directly into the clinical workflow, NeoGenomics aims to reduce friction for physicians and health systems, potentially accelerating adoption of precision medicine approaches. This move highlights the increasing importance of digital health infrastructure for diagnostic companies seeking to expand their reach and compete effectively.
What we're watching
- Adoption Rate
- The actual adoption rate of NeoGenomics’ testing services through Epic Aura will be a key indicator of the integration's success and the validity of the projected 20-30% increase in test adoption per site.
- Competitive Response
- Other diagnostic companies will likely evaluate the impact of this integration and may accelerate their own EHR integration efforts, potentially intensifying competition within the oncology diagnostics market.
- Financial Impact
- The integration’s impact on NeoGenomics’ revenue growth and profitability will be crucial to monitor, as it represents a significant investment in digital health infrastructure.
Related topics